Based on published clinical guidance · Last updated 29 October 2026
Yes; glaucoma can be present before you notice a change in your sight. The ICO describes early disease as potentially symptomless, while established optic-nerve damage cannot be reversed. Clear reading vision and comfortable eyes therefore do not rule it out. An examination checks the nerve and visual field rather than relying only on your symptoms. [1][21]
No; glaucoma affects the optic nerve, while cataract affects the natural lens. They can occur together and contribute differently to visual difficulty. The HSE/ICO Model of Eye Care describes glaucoma management as preventing further field loss, so removing a cataract does not automatically treat glaucoma or restore vision already lost through nerve damage. [2]
Yes; normal-tension glaucoma can occur even when untreated pressure readings fall within the usual range. AAO’s POAG guidance states that lowering pressure can still be beneficial. The clinician considers nerve changes, field defects and the overall examination, so a normal reading does not cancel a suspicious scan or establish that treatment is unnecessary. [6][23]
No; ocular hypertension means elevated pressure without established glaucomatous damage. AAO’s glaucoma-suspect guidance distinguishes this from confirmed glaucoma and recommends considering risk factors and evidence of change. Some people need treatment and others observation. Ask whether your referral concerns pressure alone, a suspicious nerve, a field defect or a combination of findings. [7]
Yes; glaucoma can cause permanent sight loss and blindness, particularly if it is not detected and treated. That outcome is not inevitable. AAO explains that early treatment can often prevent blindness from glaucoma. Treatment and monitoring protect remaining sight, so keep appointments even when you notice no change, and discuss your individual outlook rather than assuming the worst. [6][21]
Glaucoma develops when the optic nerve is damaged; raised eye pressure is an important cause of damage, but not the only factor. Fluid may drain too slowly or the drainage angle may become blocked. NEI explains that some people develop glaucoma at normal pressure because optic nerves differ in their tolerance. Examination identifies the type and relevant risks. [23]
Glaucoma can run in families, but inheriting a higher risk does not mean you will certainly develop it. ICO identifies family history as a risk factor, and AAO explains that inherited genes contribute to many cases. Close relatives should mention your diagnosis at eye examinations; their assessment schedule depends on their own findings and risk. [1][26]
The risk varies; OHTS reported glaucoma in 4.4% of the medication group and 9.5% of the observation group at 60 months. These are study results for people with high eye pressure but no established glaucoma, not a personal forecast. Treatment decisions consider your nerve, fields, pressure and other risk factors rather than applying the study average to everyone. [12]
Assessment usually combines pressure measurement, optic-nerve examination, drainage-angle assessment and visual-field testing, with corneal measurements and imaging where appropriate. AAO’s examination benchmarks list these complementary elements. A pressure check or photograph alone does not provide the full assessment. Bring earlier results so the clinician can compare findings rather than interpret each test in isolation. These are general diagnostic methods, not a fixed first-visit package. [19][22]
The drainage angle helps determine which type of glaucoma or angle-closure risk is present. EGS recommends gonioscopy during glaucoma or ocular-hypertension assessment and states that angle imaging does not replace it. The examination uses a special lens. Its findings can change the treatment discussion, including whether a proposed laser approach is suitable. [4]
They provide different information and may both be useful. OCT assesses structural changes around the nerve and retina, while a field test measures visual function. AAO describes these as complementary for detecting progression. The clinician interprets them alongside examination and previous results; a reassuring scan does not automatically replace repeat field testing. [6][19]
There is no guaranteed way to prevent glaucoma developing, but early detection and treatment can reduce avoidable sight loss. In people with ocular hypertension, OHTS showed that pressure-lowering treatment reduced the chance of developing glaucoma during follow-up. The decision to treat depends on individual risk. Regular examinations matter, especially with a family history; supplements are not a proven substitute. [12][4]
No; the simulator is an educational illustration, not a forecast of your sight. EGS bases assessment on measured visual function, nerve findings and change over time, not a scene overlay. Patchy loss varies between people and eyes. The slider does not represent a clinical stage, and its appearance cannot determine whether you have glaucoma or can drive. [4][22][24]
Chronic open-angle glaucoma is usually painless, so feeling comfortable does not rule it out or show that treatment is working. Acute angle closure is different: sudden severe eye pain, redness, blur, halos or nausea can be an emergency. NEI advises immediate medical assessment for these symptoms. Do not wait for your routine review or drive yourself with impaired vision. [8][18]
Treatment cannot reverse established glaucomatous optic-nerve damage; its purpose is to preserve remaining sight. The ICO emphasises early detection and pressure control for this reason. If vision changes, assessment also looks for other causes that may be treatable. Ask which part of your difficulty is attributable to glaucoma and what treatment can realistically achieve. [1]
Your target is individual to each eye and can change with the disease course. EGS advises against a universal target for everyone. The amount of damage, progression, general health and treatment burden influence the decision. Ask what target is being used, why it was chosen and what would prompt the clinician to reconsider it. [4]
No; suitable patients can discuss SLT as an initial option. NICE recommends it for newly diagnosed, non-advanced chronic open-angle glaucoma, with specific exclusions and a different approach for advanced disease. Drops remain useful if laser is unsuitable, declined or insufficient. The choice should reflect the diagnosis, examination, likely benefits, risks and your preferences. [5][9]
At 36 months, 74.2% of patients initially allocated to SLT needed no drops to maintain target pressure. LiGHT studied previously untreated open-angle glaucoma or ocular hypertension under a structured monitoring pathway. The result supports discussing laser first, but it does not guarantee that your eye will remain controlled without further laser, drops or surgery. [10]
No; the six-year result does not describe permanent control after a single laser session. The extension reported 69.8% of eyes initially treated with SLT at or below target without medical or surgical treatment, and repeat SLT was allowed. The percentage refers to eyes and the trial pathway, so it should not be presented as a personal lifetime success rate. [11]
Cochrane found that trabeculoplasty may slow visual-field progression compared with drops, with uncertainty varying by outcome and comparison. The review includes different laser technologies, so older argon-laser findings should not automatically be applied to modern SLT. Its conclusions support a balanced treatment discussion rather than a claim that laser works better for every eye. [9]
Yes; researchers re-examined LiGHT visual-field tests in an analysis published in 2026 and found less average worsening with laser first. They were studying information already collected in the original trial, rather than testing a new group of patients. The result adds useful evidence, but your own field tests and eye examinations still guide treatment. [20]
SLT is generally performed as an outpatient treatment using anaesthetic drops and a lens against the eye. Moorfields describes brief discomfort, temporary blur, inflammation and pressure rises as possible effects. Severe pain or sudden worsening of vision afterwards needs urgent advice. Continue prescribed treatment unless your clinician changes it, and arrange safe transport if vision is affected. [16]
Pressure-lowering treatment can protect visual function, rather than simply improve a reading. The placebo-controlled UK Glaucoma Treatment Study found better visual-field preservation with latanoprost than placebo. That result supports treatment when indicated, but does not select the right medicine for every person. Your response and tolerance need review alongside pressure, nerve findings and fields. [13]
Use each medicine as prescribed and leave at least 5 minutes between different drops, as Moorfields advises. Wash your hands, avoid touching the bottle tip to the eye or lashes, and check product-specific storage and expiry instructions. If handling the bottle is difficult, ask about an aid or a demonstration rather than guessing whether the dose went in. [17]
Report the problem so the treatment can be reviewed rather than silently stopping it. NICE recommends checking adherence, technique, intolerance and relevant health conditions when pressure control is inadequate. A different preparation, treatment approach or practical aid may help. Bring the bottles and explain which medicine causes symptoms and how often you actually manage to use it. [5][17]
No; surgery depends on disease severity, pressure control and the balance of benefits and risks. TAGS found advantages for initial trabeculectomy in advanced glaucoma, but that evidence does not apply automatically to every early diagnosis. Ask why an operation is being considered, what alternatives remain and what postoperative support the proposed procedure would require. [15]
Your review interval depends on progression risk and pressure control. NICE suggests 12–18 months for controlled chronic open-angle glaucoma with no detected progression and low clinical risk, versus 6–12 months for high risk. Uncertain progression or uncontrolled pressure can require earlier review. These examples are guideline categories, not this clinic’s fixed appointment schedule. [5]
You may be able to drive if you meet the Irish visual standards. RSA Group 1 requires at least 120° horizontally, specified extensions, and no defects in the central 20°. Other vision requirements also apply. Obtain professional assessment and inform the NDLS and insurer when a condition may affect safe driving; a simulator cannot establish fitness. [3][25]
They can affect comfort or eye pressure, but do not replace treatment. AAO supports aerobic activity while cautioning about head-down positions and excess caffeine. Studies suggest temporary pressure rises with screen use; they do not prove that ordinary screen use worsens glaucoma damage. Take comfortable breaks and discuss strenuous exercise or advanced disease with your eye-care clinician. [26][27]
Sudden severe eye pain, redness, blurred vision, halos or nausea need emergency assessment because acute angle closure is possible. AAO guidance distinguishes this from chronic open-angle disease. Sudden loss of vision or severe symptoms after treatment also need urgent advice. If the eye-care team is unavailable, attend an emergency department rather than waiting for routine review. [8][18]
